ENDO: Primary Aldosteronism Screening Recommended for All With Hypertension
By Elana Gotkine HealthDay Reporter
FRIDAY, July 18, 2025 -- All individuals with hypertension should be screened for primary aldosteronism (PA), according to a clinical practice guideline issued by the Endocrine Society and published online July 14 in the Journal of Clinical Endocrinology & Metabolism. The guideline was published to coincide with ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.
Gail K. Adler, M.D., Ph.D., from Brigham and Women's Hospital in Boston, and colleagues developed an updated guideline for identifying and managing PA to improve diagnosis rates and encourage targeted treatment.
The authors suggest screening all individuals with hypertension for PA by measuring aldosterone and renin and determining the aldosterone-to-renin ratio, with the results guiding subsequent clinical care. Individuals with PA should receive medical or surgical PA-specific therapy. In individuals who screen positive for PA, commencement of PA-specific medical therapy is suggested in those who do not desire or are not candidates for surgery and in situations where the probability of lateralizing PA is low based on screening results. Aldosterone suppression testing is suggested in situations in which screening results indicate an intermediate probability for lateralizing PA and patients wish to pursue eligibility for surgical therapy. Adrenal lateralization with computed tomography scanning and adrenal venous sampling is suggested prior to deciding the treatment approach in those who test positive by aldosterone suppression testing and in those in whom screening results show a high probability of lateralizing PA. In the medical treatment of PA, mineralocorticoid receptor antagonists are suggested over epithelial sodium-channel inhibitors.
"With a low-cost blood test, we could identify more people who have primary aldosteronism and ensure they receive the proper treatment for the condition," Adler said in a statement.
Several authors disclosed ties to the pharmaceutical and biotechnology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Delays in HTN Diagnosis Linked to Delays in Medication Prescribing
THURSDAY, July 17, 2025 -- Delays in diagnosis of hypertension are common and associated with delays in treatment initiation, according to a study published online July 14 in JAMA...
Nocturnal Hypertension Control Improved With Bedtime Antihypertensive Dosing
WEDNESDAY, July 16, 2025 -- Bedtime dosing with antihypertensive medication yields better nocturnal blood pressure control and improved circadian rhythm, according to a study...
Hypertension Deaths From Excessive Alcohol Use Are Increasing
THURSDAY, July 3, 2025 -- The estimated mean annual number of hypertension deaths from excessive alcohol use was higher in 2020-2021 than in 2016-2017, with a higher increase...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.